Allogene Therapeutics
Annie Yoshiyama is a seasoned finance executive currently serving as Senior Vice President of Finance and Corporate Controller at Allogene Therapeutics since April 2024. Prior to this role, Annie held the position of VP Finance and Corporate Controller at AN2 Therapeutics, where responsibilities included leading quarterly Audit Committee meetings and managing financial reporting. Annie's extensive experience at Tricida, Inc. included roles as Senior Vice President of Finance and Chief Accounting Officer, where notable achievements included overseeing a $42M equity financing and building a high-performing finance team. Previous positions at Dolby Laboratories and PwC further enriched Annie's expertise in financial reporting, technical accounting, and auditing. Annie holds both a Master's and Bachelor's degree in Accounting from the University of Southern California.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.